| 
   
  
    | Note 9. | 
    Stock-Based Compensation | 
 
   
  
Stock-based compensation expense is as follows:  
  
    | Employee stock-based compensation expense | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
 
    |   | 
  | 
    Three Months
    Ended September 30, | 
  | 
  | 
    Six Months
    Ended September 30, | 
  | 
 
  
    | (In thousands) | 
  | 
    2021 | 
  | 
  | 
    2020 | 
  | 
  | 
    2021 | 
  | 
  | 
    2020 | 
  | 
 
  
    | Cost of revenues | 
  | 
    $ | 
– | 
  | 
  | 
    $ | 
(6 | 
) | 
  | 
    $ | 
– | 
  | 
  | 
    $ | 
(27 | 
) | 
 
  
    | Research and development | 
  | 
      | 
– | 
  | 
  | 
      | 
40 | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
26 | 
  | 
 
  
    | Selling, general and administrative | 
  | 
      | 
55 | 
  | 
  | 
      | 
126 | 
  | 
  | 
      | 
114 | 
  | 
  | 
      | 
224 | 
  | 
 
  
    | Total stock-based compensation | 
  | 
    $ | 
55 | 
  | 
  | 
    $ | 
160 | 
  | 
  | 
    $ | 
114 | 
  | 
  | 
    $ | 
223 | 
  | 
 
   
  
At September 30, 2021, there were unrecognized
compensation costs of $497,000 related to stock options which is expected to be recognized over a weighted-average amortization period
of 2.27 years. 
  
At September 30, 2021, there were no unrecognized
compensation costs related to restricted stock. 
  
Stock options award activity is as follows:  
  
    | Schedule of option activity | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
 
    |   | 
  | 
    Number of  Shares | 
  | 
  | 
    Weighted-  Average  Exercise Price | 
  | 
  | 
    Weighted-  Average  Contractual Term | 
  | 
  | 
    Aggregate  Intrinsic  Value | 
  | 
 
  
    | Outstanding at April 1, 2021 | 
  | 
      | 
267,569 | 
  | 
  | 
    $ | 
25.16 | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
 
  
    | Options granted | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
 
  
    | Options exercised | 
  | 
      | 
(44,042 | 
) | 
  | 
      | 
4.38 | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
154,597 | 
  | 
 
  
    | Options forfeited | 
  | 
      | 
(3,500 | 
) | 
  | 
      | 
8.03 | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
 
  
    | Options expired | 
  | 
      | 
(13,268 | 
) | 
  | 
      | 
87.48 | 
  | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
 
  
    | Outstanding at September 30, 2021 | 
  | 
      | 
206,759 | 
  | 
  | 
    $ | 
25.88 | 
  | 
  | 
      | 
7.70 | 
  | 
  | 
    $ | 
52,023 | 
  | 
 
  
    | Exercisable at September 30, 2021 | 
  | 
      | 
86,928 | 
  | 
  | 
    $ | 
50.48 | 
  | 
  | 
      | 
5.53 | 
  | 
  | 
    $ | 
52,023 | 
  | 
 
   
  
The aggregate intrinsic value of stock options
is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common
stock, or $5.58 per share at September 30, 2021. 
  
Restricted stock award activity is as follows:  
  
    | Schedule of unvested restricted stock activity | 
  | 
      | 
  | 
  | 
  | 
      | 
  | 
  | 
 
    |   | 
  | 
    
 Number of  Shares 
 | 
  | 
  | 
    
 Weighted  Average Award  Date Fair Value  per Share 
 | 
  | 
 
  
    | Unvested restricted stock awards outstanding at April 1, 2021 | 
  | 
      | 
833 | 
  | 
  | 
    $ | 
13.68 | 
  | 
 
  
    | Restricted stock awards granted | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
 
  
    | Restricted stock awards vested | 
  | 
      | 
833 | 
  | 
  | 
      | 
13.68 | 
  | 
 
  
    | Restricted stock awards forfeited | 
  | 
      | 
– | 
  | 
  | 
      | 
– | 
  | 
 
  
    | Unvested restricted stock awards outstanding at September 30, 2021 | 
  | 
      | 
– | 
  | 
  | 
    $ | 
– | 
  | 
 
   
  
The Company did not capitalize any cost associated with stock-based
compensation. 
  
The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards. 
  
The Company issues new shares of common stock
upon exercise of stock-based awards. 
  
 |